Physician profile
Mark D Benton
NPI 1295765063
$3,417.64
in general payments reported to CMS, 2019-2025
25 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.78 · 2021: $304 · 2022: $192 · 2023: $455 · 2024: $1,343 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.32 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $517.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $482.45 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $335.42 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $314.44 | 2022-2025 | Vraylar, Viberzi, Linzess |
| Supernus Pharmaceuticals, INC. | $287.02 | 2023-2025 | Qelbree, Qelbree |
| Dexcom, INC. | $158.76 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $120.30 | 2024 | Korlym |
| Corium, LLC | $102.89 | 2025 | Azstarys |
| Tris Pharma INC | $72.81 | 2023-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $60.55 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $56.92 | 2025 | |
| Glaxosmithkline, LLC. | $54.82 | 2021-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $46.34 | 2025 | Auvelity, Sunosi |
| Sumitomo Pharma America, INC. | $45.77 | 2024-2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.40 | 2024 | Freestyle Libre 3 |
| Almatica Pharma LLC | $23.42 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $19.56 | 2025 | Rexulti |
| Eisai INC. | $16.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.91 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $12.97 | 2021 | |
| Genentech USA, INC. | $12.49 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.